Skip to main content
Top
Metadata
Title
Novel vascular targeting/disrupting agents: Combretastatin A4 phosphate and related compounds
Authors
Matthew M. Cooney, MD
Jose Ortiz, MD
Ronald M. Bukowski, MD
Scot C. Remick, MD
Publication date
01-04-2005
Publisher
Current Medicine Group
Published in
Current Oncology Reports / Issue 2/2005
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-005-0033-x

Other articles of this Issue 2/2005

Current Oncology Reports 2/2005 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine